FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200019954> ?p ?o ?g. }

• W4200019954 abstract "AXL-mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti-tumor and anti-metastatic activities of SKI-G-801, a small-molecule inhibitor of AXL, alone and in combination with anti-PD-1 therapy.In vitro pAXL inhibition by SKI-G-801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti-metastatic potential of SKI-G-801. Furthermore, SKI-G-801, anti-PD-1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.SKI-G-801 robustly inhibited pAXL expression in various cell lines. SKI-G-801 alone or in combination with anti-PD-1 potently inhibited metastasis in B16F10 melanoma, CT26 colon and 4T1 breast models. SKI-G-801 inhibited the growth of B16F10 and 4T1 tumor-bearing mice but not immune-deficient mice. An antibody depletion assay revealed that CD8+ T cells significantly contributed to SKI-G-801-mediated survival. Anti-PD-1 and combination group were observed the increased CD8+Ki67+ and effector T cells and M1 macrophage and decreased M2 macrophage, and granulocytic myeloid-derived suppressor cell (G-MDSC) compared to the control group. The neoadjuvant combination of SKI-G-801 and anti-PD-1 therapy achieved superior survival benefits by inducing more profound T-cell responses in the 4T1 syngeneic mouse model.SKI-G-801 significantly suppressed tumor metastasis and growth by enhancing anti-tumor immune responses. Our results suggest that SKI-G-801 has the potential to overcome anti-PD-1 therapy resistance and allow more patients to benefit from anti-PD-1 therapy." @default.
• W4200019954 created "2021-12-31" @default.
• W4200019954 creator A5000828978 @default.
• W4200019954 creator A5001402338 @default.
• W4200019954 creator A5006291712 @default.
• W4200019954 creator A5011458812 @default.
• W4200019954 creator A5011980528 @default.
• W4200019954 creator A5012382352 @default.
• W4200019954 creator A5018069766 @default.
• W4200019954 creator A5021973162 @default.
• W4200019954 creator A5022124273 @default.
• W4200019954 creator A5023886728 @default.
• W4200019954 creator A5024745631 @default.
• W4200019954 creator A5027007415 @default.
• W4200019954 creator A5030137859 @default.
• W4200019954 creator A5032070864 @default.
• W4200019954 creator A5033869632 @default.
• W4200019954 creator A5036720036 @default.
• W4200019954 creator A5039735690 @default.
• W4200019954 creator A5047490140 @default.
• W4200019954 creator A5047855870 @default.
• W4200019954 creator A5048561149 @default.
• W4200019954 creator A5049113012 @default.
• W4200019954 creator A5052815304 @default.
• W4200019954 creator A5054908841 @default.
• W4200019954 creator A5055333102 @default.
• W4200019954 creator A5055809530 @default.
• W4200019954 creator A5056943513 @default.
• W4200019954 creator A5062609911 @default.
• W4200019954 creator A5062742438 @default.
• W4200019954 creator A5064697305 @default.
• W4200019954 creator A5073039234 @default.
• W4200019954 creator A5074156620 @default.
• W4200019954 creator A5074492070 @default.
• W4200019954 creator A5081221518 @default.
• W4200019954 creator A5082442075 @default.
• W4200019954 date "2021-12-29" @default.
• W4200019954 modified "2023-10-16" @default.
• W4200019954 title "SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models" @default.
• W4200019954 cites W1534535586 @default.
• W4200019954 cites W1612634664 @default.
• W4200019954 cites W1971574117 @default.
• W4200019954 cites W1997522623 @default.
• W4200019954 cites W2043841986 @default.
• W4200019954 cites W2083870593 @default.
• W4200019954 cites W2092109670 @default.
• W4200019954 cites W2132626958 @default.
• W4200019954 cites W2134585145 @default.
• W4200019954 cites W2149320436 @default.
• W4200019954 cites W2153566723 @default.
• W4200019954 cites W2299181842 @default.
• W4200019954 cites W2314772977 @default.
• W4200019954 cites W2326866882 @default.
• W4200019954 cites W2331506181 @default.
• W4200019954 cites W2401056916 @default.
• W4200019954 cites W2521503673 @default.
• W4200019954 cites W2561086413 @default.
• W4200019954 cites W2563663251 @default.
• W4200019954 cites W2593026932 @default.
• W4200019954 cites W2596133050 @default.
• W4200019954 cites W2610858500 @default.
• W4200019954 cites W2620546513 @default.
• W4200019954 cites W2727463864 @default.
• W4200019954 cites W2763275642 @default.
• W4200019954 cites W2772677509 @default.
• W4200019954 cites W2798160602 @default.
• W4200019954 cites W2894796660 @default.
• W4200019954 cites W2982428167 @default.
• W4200019954 cites W2987630755 @default.
• W4200019954 cites W3008792561 @default.
• W4200019954 cites W79483467 @default.
• W4200019954 doi "https://doi.org/10.1002/cti2.1364" @default.
• W4200019954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35003748" @default.
• W4200019954 hasPublicationYear "2021" @default.
• W4200019954 type Work @default.
• W4200019954 citedByCount "5" @default.
• W4200019954 countsByYear W42000199542022 @default.
• W4200019954 countsByYear W42000199542023 @default.
• W4200019954 crossrefType "journal-article" @default.
• W4200019954 hasAuthorship W4200019954A5000828978 @default.
• W4200019954 hasAuthorship W4200019954A5001402338 @default.
• W4200019954 hasAuthorship W4200019954A5006291712 @default.
• W4200019954 hasAuthorship W4200019954A5011458812 @default.
• W4200019954 hasAuthorship W4200019954A5011980528 @default.
• W4200019954 hasAuthorship W4200019954A5012382352 @default.
• W4200019954 hasAuthorship W4200019954A5018069766 @default.
• W4200019954 hasAuthorship W4200019954A5021973162 @default.
• W4200019954 hasAuthorship W4200019954A5022124273 @default.
• W4200019954 hasAuthorship W4200019954A5023886728 @default.
• W4200019954 hasAuthorship W4200019954A5024745631 @default.
• W4200019954 hasAuthorship W4200019954A5027007415 @default.
• W4200019954 hasAuthorship W4200019954A5030137859 @default.
• W4200019954 hasAuthorship W4200019954A5032070864 @default.
• W4200019954 hasAuthorship W4200019954A5033869632 @default.
• W4200019954 hasAuthorship W4200019954A5036720036 @default.
• W4200019954 hasAuthorship W4200019954A5039735690 @default.
• W4200019954 hasAuthorship W4200019954A5047490140 @default.
• W4200019954 hasAuthorship W4200019954A5047855870 @default.
• W4200019954 hasAuthorship W4200019954A5048561149 @default.
• W4200019954 hasAuthorship W4200019954A5049113012 @default.

• next